StockNews.com Upgrades MediWound (NASDAQ:MDWD) to Sell

MediWound (NASDAQ:MDWD) was upgraded by investment analysts at StockNews.com to a “sell” rating in a research report issued to clients and investors on Monday.

Several other equities analysts have also recently issued reports on the company. Maxim Group boosted their price target on MediWound from $25.00 to $30.00 and gave the company a “buy” rating in a research report on Tuesday, July 16th. HC Wainwright reiterated a “buy” rating and issued a $28.00 price target on shares of MediWound in a report on Tuesday, July 16th.

MediWound Price Performance

Shares of MediWound stock traded down $1.13 on Monday, reaching $16.35. The company had a trading volume of 149,637 shares, compared to its average volume of 110,366. The firm’s 50-day moving average price is $17.26 and its two-hundred day moving average price is $16.00. MediWound has a 1 year low of $7.10 and a 1 year high of $24.00. The firm has a market cap of $151.73 million, a price-to-earnings ratio of -11.85 and a beta of 0.81.

MediWound (NASDAQ:MDWD) last posted its quarterly earnings results on Wednesday, May 29th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.01. The business had revenue of $4.96 million for the quarter, compared to the consensus estimate of $4.65 million. MediWound had a negative return on equity of 21.67% and a negative net margin of 64.24%. As a group, analysts anticipate that MediWound will post -1.86 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Essex Investment Management Co. LLC increased its position in shares of MediWound by 241.6% during the first quarter. Essex Investment Management Co. LLC now owns 132,487 shares of the biopharmaceutical company’s stock worth $1,888,000 after acquiring an additional 93,705 shares in the last quarter. Yelin Lapidot Holdings Management Ltd. grew its holdings in shares of MediWound by 45.7% during the 4th quarter. Yelin Lapidot Holdings Management Ltd. now owns 125,493 shares of the biopharmaceutical company’s stock valued at $1,276,000 after purchasing an additional 39,348 shares during the last quarter. Janney Montgomery Scott LLC bought a new stake in MediWound during the 1st quarter worth approximately $427,000. Rosalind Advisors Inc. grew its holdings in MediWound by 5.7% during the 2nd quarter. Rosalind Advisors Inc. now owns 513,490 shares of the biopharmaceutical company’s stock worth $7,969,000 after acquiring an additional 27,500 shares during the last quarter. Finally, Bank of New York Mellon Corp acquired a new position in shares of MediWound in the 2nd quarter worth approximately $342,000. Institutional investors and hedge funds own 46.83% of the company’s stock.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.